IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: .

C. Soto-Jara

Art Unit

1646

Serial No.

09/706,540

Filed

November 4, 2000

For

PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE

TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH

PATHOLOGICAL PRECURSOR THEREOF

Office of the Initial Patent Examination's Customer Service Center Assistant Commissioner for Patents Washington, D.C. 20231

JUN 1 9 2001

FEB 2 0 200

which

TECH CENTER 1600/2900

REQUEST FOR CORRECTED FILING RECEIPT

1.	Attached is a copy of A CORRECTED official filing receipt from the PTO in the subject application	on		
	issuance of a newly corrected filing receipt is respectfully requested.			

2. A check in the amount of \$240.00 is enclosed to cover the payment of 3 Independent Claims.

2.	There is an error	with respect to the	following d	ata which is
	Χ	incorrectly entered	and	lor 🗆

Χ incorrectly entered and/or

omitted.

3. Complete the following applicable item A or B:

Χ A.

The correction(s) is/are not due to any error by applicant(s) and no fee is due.

B.

At least one of the above corrections is due to applicant's error and the fee therefor under 37 CFR 1.19(h) of \$25.00 should be charged to Account No.

ERROR IN

CORRECT DATA

□ Applicants' Names	1.
2. X Applicants' Addresses	2. Laconnex, Geneva, Switzerland
3. □ Title	3.
4, ☐ Filing Date	4.
5. ☐ Serial Number	5.
6. ☐ Foreign/PCT Application Re:	6.
7. X Other Number of Independent Claims	p. 6
Gibbons, Del Deo, Dolan, Griffinger & Vecchione	ione of seviens

Gibbons, Del Deo, Dolan, Griffinger & Vecchione

One Riverfront Plaza

Newark NJ 07102-5497 02/28/2001 SSANDARA 00000005 09706540 Diane L. Ferrone (Registration No. 36,135)

Attorney for Applicant(s)

Tel:

(973) 596-4879

01 FC:102

240.00 OP

Fax:: (973) 639-6337

CERTIFICATE OF MAILING (37 CFR 1.8(a))

I hereby certify that this paper (along with any paper referred to as being transmitted therewith) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231.

Signature:

alderou

Date:

February 16, 2001

(Print Name)

Tracie Calderone



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

www.uspto.gov

IND CLAIMS FIL FEE REC'D ATTY.DOCKET.NO DRAWINGS TOT CLAIMS GRP ART UNIT FILING DATE APPLICATION NUMBER **AXONYX-**16 8 19 710 11/04/2000 1646 09/706,540 NYU-4

26345 GIBBONS, DEL DEO, DOLAN, GRIFFINGER & VECCHIONE 1 RIVERFRONT PLAZA NEWARK, NJ 07102-5497

FILING RECEIPT OC000000005756745*

Date Mailed: 02/12/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Claudio Soto-Jara, Residence, NOT PROVIDED; Laconnex, Geneva, Surfficient Children C

Continuing Data as Claimed by Applicant

Foreign Applications

If Required, Foreign Filing License Granted 02/12/2001

Title

Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof

Preliminary Class

530

Data entry by : DILLON, LAWANDA

Team: OIPE

Date: 02/12/2001





LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application.
 They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:





UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.uspto.gov

Bib Data Sheet

CONFIRMATION NO. 6335

SERIAL NUMBER 09/706,540	FILING DATE 11/04/2000 RULE	CLASS	GROUP ART 1647	UNIT	ATTORNEY DOCKET NO. AXONYX-NYU-4					
APPLICANTS Claudio Soto-Jara, Laconnex Geneva, SWITZERLAND; RECEIVE										
** CONTINUING DATA **********************************										
	ATIONS ************************************									
Foreign Priority claimed 35 USC 119 (a-d) conditions										
ADDRESS 26345										
TITLE Peptide analogs and r protein folding into an	mimetics suitable for in nyloid, amyloid-like de	vivo use in the treatr	nent of disease	es associa precurso	ated with abnormal or thereof					
				ees	Tiling)					
RECEIVED No	S: Authority has been g	□ 1.17	1.16 Fees (Filing) 1.17 Fees (Processing Ext. of time)							
1080 No	o for following:):		☐ 1.18 Fees (Issue) ☐ Other						
			☐ Cred	dit						